In Vitro and In Vivo Antifungal Activity of Amphotericin B Lipid Complex: Are Phospholipases Important?

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  1998-04-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1128/AAC.42.4.767PMID 9559780PMCID PMC105539
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis

  1997cited by this paper
• Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses

  1997cited by this paper
• Behavior of amphotericin B lipid complex in plasma in vitro and in the circulation of rats

  1997cited by this paper
• Evidence of multiple extracellular phospholipase activities of Aspergillus fumigatus

  1996cited by this paper
• Amphotericin B lipid complex: Review of safety, pharmacokinetics and efficacy

  1996cited by this paper
• Evidence implicating phospholipase as a virulence factor of Candida albicans

  1995cited by this paper
• Comparison of the activity of free and liposomal amphotericin B in vitro and in a model of systemic and localized murine candidiasis.

  1994cited by this paper
• In vitro and in vivo antifungal activities of liposomal amphotericin B, and amphotericin B lipid complex

  1994cited by this paper
• Host cell-fungal cell interactions.

  1994cited by this paper
• Mechanisms by which Candida albicans induces endothelial cell prostaglandin synthesis

  1994cited by this paper
• Antifungal susceptibility testing

  1993cited by this paper
• Extracellular phospholipase A2 expression and inflammation: the relationship with associated disease states.

  1993cited by this paper
• Amphotericin B Lipid Complex (Ablc™): A Molecular Rationale for the Attenuation of Amphotericin B Related Toxicities

  1993cited by this paper
• Efficacies of ampbotericin B lipid complex (ABLC) and conventional amphotericin B against marine coccidioidomycosis

  1992cited by this paper
• Efficacies of amphotericin B lipid complex (ABLC) and conventional amphotericin B against murine coccidioidomycosis.

  1992cited by this paper
• Comparison of antifungal activity of amphotericin B deoxycholate suspension with that of amphotericin B cholesteryl sulfate colloidal dispersion

  1992cited by this paper
• Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity.

  1992cited by this paper
• Amphotericin B lipid complex therapy of experimental fungal infections in mice

  1991cited by this paper
• Comparative efficacies of amphotericin B lipid complex and amphotericin B deoxycholate suspension against murine blastomycosis

  1991cited by this paper
• Comparative in vitro effects of liposomal amphotericin B, amphotericin B-deoxycholate, and free amphotericin B against fungal strains determined by using MIC and minimal lethal concentration susceptibility studies and time-kill curves

  1991cited by this paper
• Unusual lipid structures selectively reduce the toxicity of amphotericin B.

  1988influential reference
• Plate method for detection of phospholipase activity in Candida albicans.

  1982cited by this paper
• National Committee for Clinical Laboratory Standards.

  1980cited by this paper
• Manual of clinical microbiology

  1975cited by this paper

• Aspergillus Section Terrei and Antifungals: From Broth to Agar-Based Susceptibility Testing Methods

  2023cites this paper
• Amphotericin B-PEG Conjugates of ZnO Nanoparticles: Enhancement Antifungal Activity with Minimal Toxicity

  2022cites this paper
• Cyclodextrin-based Pickering nanoemulsions containing amphotericin B: Part II. Formulation, antifungal activity, and chemical stability

  2022cites this paper
• SELEX- Aptamer Technology to Combat Diseases of Animals : Recent Advancement and Future Application: A Review

  2021cites this paper
• Nanomaterials and nanocomposite applications in veterinary medicine

  2020cites this paper
• [Antimicrobial activity of Rosmarinus officinalis and Zingiber officinale extracts on the species of the genus Candida and on Streptococcus pneumonia.]

  2020cites this paper
• In Vitro and In Vivo Study of Amphotericin B Formulation with Quaternized Bioreducible Lipidoids.

  2020cites this paper
• Neonatal candidiasis.

  2020cites this paper
• Immunomodulatory Properties of Antifungal Agents on Immune Functions of the Host

  2019cites this paper
• Theranostics Aspects of Various Nanoparticles in Veterinary Medicine

  2018cites this paper
• Antifungal activity of Camellia sinensis crude extracts against four species of Candida and Microsporum persicolor.

  2018cites this paper
• Anticandidal activity of Inula helenium root essential oil: Synergistic potential, anti-virulence efficacy and mechanism of action

  2018cites this paper
• 156 – Systemic Antifungal Agents

  2017cites this paper
• Comparison of Mycobacterium tuberculosis complex Yield and Contamination Rates using Lowenstein-Jensen with and without Antibiotics in Western Kenya.

  2017cites this paper
• Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients

  2017cites this paper
• Antifungal activity of acetone extracts from Punica granatum L., Quercus suber L. and Vicia faba L.

  2017cites this paper
• Super aggregated form of Amphotericin B: a novel way to increase its therapeutic index.

  2016cites this paper
• Amphotericin B Formulations: A Comparative Review of Efficacy and Toxicity

  2013cites this paper
• Pharmacodynamics and pharmacokinetics of antifungals for treatment of invasive aspergillosis.

  2013cites this paper
• Antifungals in Systemic Neonatal Candidiasis

  2012cites this paper
• Immunomodulatory Properties of Antifungal Agents on Phagocytic Cells

  2011cites this paper
• Antifungal Therapy in Patients with Hematological Malignancies

  2011cites this paper
• Amphotericin B in neonates: deoxycholate or lipid formulation as first-line therapy – is there a ‘right’ choice?

  2011cites this paper
• Amphotericin B resistance leads to enhanced proteinase and phospholipase activity and reduced germ tube formation in Candida albicans.

  2010cites this paper
• Amphotericin B-Induced Nephrotoxicity

  2010cites this paper
• Nanosomal Amphotericin B is an efficacious alternative to Ambisome for fungal therapy.

  2010cites this paper
• Antifungal treatment of small animal veterinary patients.

  2010cites this paper
• Recent Approaches to Antifungal Therapy for Invasive Mycoses

  2009cites this paper
• The reformulation of Amphotericin B for oral administration to treat systemic fungal infections and visceral leishmaniasis

  2009cites this paper
• Safety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients

  2008cites this paper
• Interaction of amphotericin B lipid formulations and triazoles with human polymorphonuclear leucocytes for antifungal activity against Zygomycetes

  2008cites this paper
• Amphotericin B lipid preparations: what are the differences?

  2008cites this paper
• Clinical pharmacokinetics of systemically administered antimycotics.

  2007cites this paper
• Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet and AmBisome in combination with caspofungin to rats infected with Aspergillus fumigatus.

  2007cites this paper
• Eficiência terapêutica das formulações lipídicas de anfotericina B

  2006cites this paper
• Antifungal agents: mode of action in yeast cells.

  2006cites this paper
• The experience is CLEAR.

  2006cites this paper
• Plasma lipoprotein distribution of amphotericin B formulations : potential role of phospholipid transfer protein

  2006cites this paper
• The contribution of animal models of aspergillosis to understanding pathogenesis, therapy and virulence.

  2005cites this paper
• Use of amphotericin B lipid complex in elderly patients.

  2005cites this paper
• Efficacy of Abelcet and caspofungin, alone or in combination, against CNS aspergillosis in a murine model.

  2005cites this paper
• Effect of heat-treatment and the role of phospholipases on Fungizone-induced cytotoxicity within human kidney proximal tubular (HK-2) cells and Aspergillus fumigatus.

  2005cites this paper
• Management of systemic fungal infections: alternatives to itraconazole.

  2005influential citation
• Traitement des infections fongiques invasives

  2005cites this paper
• Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis.

  2004cites this paper
• Retrospective study of the renal effects of amphotericin B lipid complex when used at higher-than-recommended dosages and longer durations compared with lower dosages and shorter durations in patients with systemic fungal infections.

  2004cites this paper
• Comparative Efficacies of Four Amphotericin B Formulations—Fungizone, Amphotec (Amphocil), AmBisome, and Abelcet—against Systemic Murine Aspergillosis

  2004cites this paper
• Effect of Heat-Treated Amphotericin B on Renal and Fungal Cytotoxicity

  2004cites this paper
• Guidelines for treatment of candidiasis.

  2004cites this paper
• Efficacy, safety and cost-effectiveness of Amphotericin B Lipid Complex (ABLC): a review of the literature

  2004cites this paper
• Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer

  2003cites this paper
• Antifungal drug resistance.

  2003cites this paper
• Toxicity and Antileishmanial Activity of a New Stable Lipid Suspension of Amphotericin B

  2003cites this paper
• Amphotericin B lipid complex for the treatment of invasive fungal infections

  2003cites this paper
• The lipid formulations of amphotericin B

  2003cites this paper
• Invasive aspergillosis in liver transplant recipients: outcome comparison of therapy with amphotericin B lipid complex and a historical cohort treated with conventional amphotericin B.

  2003cites this paper
• Recommendations for the treatment of fungal pneumonias

  2003cites this paper
• Susceptibilities of phospholipid vesicles containing different sterols to amphotericin B-loaded lysophosphatidylcholine micelles.

  2003cites this paper
• Phospholipase and protease activities in clinical Candida isolates with reference to the sources of strains


  2002cites this paper
• Fungal Phospholipase Activity and Susceptibility to Lipid Preparations of Amphotericin B

  2001cites this paper
• Amphotericin B lipid complex for neonatal invasive candidiasis

  2001cites this paper
• [New lipid formulations of amphotericin B. Review of the literature].

  2001cites this paper
• Nouvelles formes lipidiques de l’amphotéricine B. Revue de la littérature

  2001cites this paper
• Potential Role of Phospholipases in Virulence and Fungal Pathogenesis

  2000cites this paper
• In-Vitro Synergistic Effect of Fluconazole with Nonsteroidal Anti-Inflammatory Agents Against Candida albicans Strains

  2000cites this paper
• Antifungal Pharmacodynamics: Review of the Literature and Clinical Applications

  2000cites this paper
• Potential role of phospholipases in virulence and fungal pathogenesis.

  2000cites this paper
• Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America.

  2000cites this paper
• Efficacy of Liposomal Amphotericin B with Prolonged Circulation in Blood in Treatment of Severe Pulmonary Aspergillosis in Leukopenic Rats

  2000cites this paper
• A Pharmacokinetic Study of Amphotericin B Lipid Complex Injection (Abelcet) in Patients with Definite or Probable Systemic Fungal Infections

  2000cites this paper
• Comparative in vitro Antifungal Activity of Amphotericin B Lipid Complex, Amphotericin B and Fluconazole

  2000cites this paper
• In Vivo Activity of Amphotericin B Lipid Complex in Immunocompromised Mice against Fluconazole-Resistant or Fluconazole-Susceptible Candida tropicalis

  2000cites this paper
• Ghannoum Virulence and Fungal Pathogenesis Potential Role of Phospholipases in

  1999cites this paper
• Novel strategies for treating candidiasis.

  1999cites this paper
• Lipid‐Based Amphotericin B for the Treatment of Fungal Infections

  1999cites this paper
• Novel antifungal drugs.

  1999cites this paper
• Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability

  1999cites this paper
• Aspergillus fumigatus and Aspergillosis

  1999cites this paper
• Antifongiques

  1999cites this paper
• Comparison of In Vitro Activity of Liposomal Nystatin againstAspergillus Species with Those of Nystatin, Amphotericin B (AB) Deoxycholate, AB Colloidal Dispersion, Liposomal AB, AB Lipid Complex, and Itraconazole

  1999cites this paper
• International Journal of Nanomedicine Dovepress How Can Micelle Systems Be Rebuilt by a Heating Process?

  year unknowncites this paper